NCT07303725

Brief Summary

This is a pilot study to evaluate the feasibility, image quality, and procedural utility of a novel spectral CT technique using Canon Medical's 4D CT system during image-guided interventional oncology procedures

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at below P25 for all trials

Timeline
4mo left

Started Feb 2025

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress80%
Feb 2025Sep 2026

Study Start

First participant enrolled

February 1, 2025

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

March 17, 2025

Completed
9 months until next milestone

First Posted

Study publicly available on registry

December 26, 2025

Completed
1 month until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2026

Completed
7 months until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2026

Expected
Last Updated

December 26, 2025

Status Verified

March 1, 2025

Enrollment Period

1 year

First QC Date

March 17, 2025

Last Update Submit

December 18, 2025

Conditions

Liver Cancer (Primary and Metastatic)Renal Cancer

Keywords

spectral CT

Outcome Measures

Primary Outcomes (1)

  • CT image

    Effective Dose and CTDI

    Baseline

Secondary Outcomes (2)

  • number

    Baseline

  • time

    Baseline

Study Arms (3)

angiography mapping

Hepatocellular carcinoma (HCC) patients undergoing hepatic angiography mapping prior to TARE (N=10)

microwave ablation

percutaneous tumor ablation in patients receiving image-guided tumor ablation using MWA (n=10)

cryoablation

cryoablation (N=10) for primary liver (HCC) or primary kidney tumors (RCC)

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

patients with liver or kidney cancer being treated at VAPAHCS

You may qualify if:

  • Age \> or = 18 years
  • Tumor in an area without prior surgical or ablative therapy
  • At least 1 tumor greater than 1.5 cm in greatest diameter

You may not qualify if:

  • Not eligible for indicated procedure.
  • BMI \> 35
  • Prior surgery.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

VA Palo Alto Healthcare System

Palo Alto, California, 94304, United States

RECRUITING

MeSH Terms

Conditions

Liver NeoplasmsNeoplasm MetastasisKidney Neoplasms

Condition Hierarchy (Ancestors)

Digestive System NeoplasmsNeoplasms by SiteNeoplasmsDigestive System DiseasesLiver DiseasesNeoplastic ProcessesPathologic ProcessesPathological Conditions, Signs and SymptomsUrologic NeoplasmsUrogenital NeoplasmsFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesKidney DiseasesUrologic DiseasesMale Urogenital Diseases

Study Officials

  • Sirish Kishore, MD

    VA Palo Alto Health Care System

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Sirish Kishore, MD

CONTACT

650-493-5000sirish.kishore@va.gov

Luisa Manfredi, MPH

CONTACT

650-493-5000luisa.manfredi1@va.gov

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 17, 2025

First Posted

December 26, 2025

Study Start

February 1, 2025

Primary Completion

February 1, 2026

Study Completion (Estimated)

September 1, 2026

Last Updated

December 26, 2025

Record last verified: 2025-03

Data Sharing

IPD Sharing
Will not share

Locations

US(1)